LEADING EDGE BIO

For the past decade, biopharma companies have invested heavily in artificial intelligence to improve target identification, protein engineering, clinical trial design, biomarker discovery, pathology, pharmacovigilance, and commercial operations. Until recently, however, relatively little attention was paid to governing those AI systems. That era is ending. The emergence of healthcare AI governance frameworks—including certification programs and industry playbooks—signals that

One of the more fascinating opportunities I encountered recently involved a highly academic organization developing an AI-driven platform intended to transform how biomedical research and pathology data are interpreted. The science was exceptional. The team consisted of world-class researchers. The technology held genuine promise to accelerate biomarker discovery, improve translational research, and ultimately support more precise drug development. The challenge wasn't the sc

One of the greatest misconceptions in biotechnology is that success comes from having the best molecule. It doesn't. More often, success comes from having the best portfolio strategy. Drug discovery is only one component of building a durable company. The organizations that consistently outperform their peers understand that every asset, indication, biomarker, companion diagnostic, platform technology, and strategic partnership should reinforce the others. They don't simply d